

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



CHINA BIOTECH SERVICES HOLDINGS LIMITED

中國生物科技服務控股有限公司

(Incorporated in the Cayman Islands and continued in Bermuda with limited liability)

(Stock code: 8037)

**(1) POLL RESULTS OF THE ANNUAL GENERAL MEETING HELD
ON 20 JUNE 2022;
(2) RE-DESIGNATION OF DIRECTOR;
(3) CHANGE OF COMPLIANCE OFFICER, AUTHORISED
REPRESENTATIVE AND AGENT FOR THE SERVICE OF PROCESS
IN HONG KONG**

The Board is pleased to announce that each of the Resolutions was duly passed by the Shareholders by way of poll at the AGM held on 20 June 2022.

With effect from the conclusion of the AGM:

- (1) Mr. Wang Zheng, an executive Director, was re-designated as a non-executive Director and ceased to be the Compliance Officer, an Authorised Representative and a Process Agent;
- (2) Mr. Liu Xiaolin, the chairman and an executive Director, was appointed as the Compliance Officer in place of Mr. Wang; and
- (3) Ms. Wong Miu Shun, the company secretary of the Company, was appointed as an Authorised Representative in place of Mr. Wang.

Reference is made to the announcement (the “**Announcement**”) and the circular (the “**Circular**”) of China Biotech Services Holdings Limited (the “**Company**”) dated 26 May 2022 and 27 May 2022 respectively. Unless otherwise specified herein, capitalised terms used in this announcement shall have the same meanings as those defined in the Announcement or the Circular.

POLL RESULTS OF THE AGM

The Board is pleased to announce that each of the proposed resolutions set out in the notice of the AGM (the “**Resolutions**”) was duly passed by the Shareholders by way of poll at the AGM held on 20 June 2022. Full text of the Resolutions is set out in the notice of the AGM, a copy of which is set out in the Circular. The poll results are as follows:

ORDINARY RESOLUTIONS		Number of Shares (%)	
		VOTED FOR	VOTED AGAINST
1.	To receive and approve the audited consolidated financial statements of the Company and its subsidiaries and the reports of the Directors and the auditors of the Company for the year ended 31 December 2021.	610,322,446 (100%)	0 (0%)
2.	(a) To re-elect Mr. Liu Xiaolin as an executive Director.	610,322,446 (100%)	0 (0%)
	(b) To re-elect Mr. Huang Song as an executive Director.	608,502,446 (99.7018%)	1,820,000 (0.2982%)
	(c) To re-elect Mr. Wang Zheng as a non-executive Director.	610,322,446 (100%)	0 (0%)
	(d) To authorise the Board to fix the respective Directors’ remuneration.	610,322,446 (100%)	0 (0%)
3.	To re-appoint RSM Hong Kong, Certified Public Accountants, as the auditors of the Company and to authorise the Board to fix its remuneration.	610,322,446 (100%)	0 (0%)
4.	To grant a general mandate to the Directors to repurchase the Shares.	610,322,446 (100%)	0 (0%)
5.	To grant a general mandate to the Directors to allot, issue and otherwise deal with the Shares.	608,502,446 (99.7018%)	1,820,000 (0.2982%)
6.	To add the number of the Shares repurchased by the Company to the mandate granted to the Directors under resolution numbered 5.	608,502,446 (99.7018%)	1,820,000 (0.2982%)

SPECIAL RESOLUTION		Number of Shares (%)	
		VOTED FOR	VOTED AGAINST
7.	To approve and adopt the New Bye-laws.	610,322,446 (100%)	0 (0%)

Note: The number of Shares and percentage of Shares voted as stated above are based on the total number of Shares held by the Shareholders who attended and voted at the AGM in person, by authorised corporate representative or by proxy.

As more than 50% of the votes were cast in favour of each of the Resolutions nos.1, 2(a), 2(b), 2(c), 2(d), 3, 4, 5 and 6, each of such Resolutions was duly passed as an ordinary resolution of the Company. As more than 75% of the votes were cast in favour of the Resolution no.7, such Resolution was duly passed as a special resolution of the Company.

As at the date of the AGM, the total number of issued Shares was 963,231,150, which was the total number of Shares entitling the Shareholders to attend and vote on each of the Resolutions at the AGM. There was no Share entitling any Shareholder to attend and abstain from voting in favour of the Resolutions at the AGM as set out in Rule 17.47A of the GEM Listing Rules. No Shareholder was required under the GEM Listing Rules to abstain from voting at the AGM and no Shareholder has stated his/her/its intention in the Circular to vote against or to abstain from voting on the Resolutions at the AGM.

All the Directors attended the AGM either in person or by electronic means.

The branch share registrar and transfer office of the Company in Hong Kong, Union Registrars Limited, was appointed as the scrutineer for the vote-taking at the AGM.

RE-DESIGNATION OF DIRECTOR, CHANGE OF COMPLIANCE OFFICER, AUTHORISED REPRESENTATIVE AND AGENT FOR THE SERVICE OF PROCESS IN HONG KONG

As disclosed in the Announcement, with effect from the conclusion of the AGM:

- (1) Mr. Wang Zheng, an executive Director, was re-designated as a non-executive Director and ceased to be the Compliance Officer, an Authorised Representative and a Process Agent;
- (2) Mr. Liu Xiaolin, the chairman and an executive Director, was appointed as the Compliance Officer in place of Mr. Wang, and currently being the other Authorised Representative and the other Process Agent, will remain as an Authorised Representative and a Process Agent; and

- (3) Ms. Wong Miu Shun, the company secretary of the Company, was appointed as an Authorised Representative in place of Mr. Wang.

By order of the Board
China Biotech Services Holdings Limited
Liu Xiaolin
Chairman and Executive Director

Hong Kong, 20 June 2022

As at the date of this announcement, the board of Directors comprises three executive Directors, namely, Mr. Liu Xiaolin (Chairman), Mr. He Xun, and Mr. Huang Song; one non-executive Director, namely, Mr. Wang Zheng; and three independent non-executive Directors, namely, Mr. Yan Guoxiang, Dr. Ho Ivan Chun Kit and Mr. Qian Hongji.

This announcement, for which the Directors collectively and individually accept full responsibility, includes particulars given in compliance with the GEM Listing Rules for the purpose of giving information with regard to the Company. The Directors, having made all reasonable enquiries, confirm that to the best of their knowledge and belief the information contained in this announcement is accurate and complete in all material respects and not misleading or deceptive; and there are no other matters the omission of which would make any statement herein or this announcement misleading.

This announcement will remain on the “Latest Listed Company Information” page of the website of The Stock Exchange of Hong Kong Limited at www.hkexnews.hk for at least 7 days from the date of its publication and on the website of the Company at www.cbshhk.com.